2019
Immunotherapy of Melanoma: Facts and Hopes
Weiss SA, Wolchok JD, Sznol M. Immunotherapy of Melanoma: Facts and Hopes. Clinical Cancer Research 2019, 25: 5191-5201. PMID: 30923036, PMCID: PMC6726509, DOI: 10.1158/1078-0432.ccr-18-1550.Peer-Reviewed Original ResearchConceptsOverall survivalMetastatic diseaseImmune therapyPredictive biomarkersNivolumab/ipilimumab combinationRandomized phase III trialLong-term clinical benefitImmunobiology of tumorsDuration of therapyPhase III trialsLong-term survivorsEffective immune therapyAdjuvant settingIpilimumab combinationMetastatic settingIII trialsPatient subsetsClinical benefitImmune modulationMetastatic melanomaClinical trialsSingle agentTherapyTrue increaseCell therapy
2017
Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy.
Lattanzi M, Lee Y, Robinson E, Weiss S, Moran U, Simpson D, Shapiro R, Berman R, Pavlick A, Wilson M, Kirchhoff T, Zhong J, Osman I. Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy. Journal Of Clinical Oncology 2017, 35: 9577-9577. DOI: 10.1200/jco.2017.35.15_suppl.9577.Peer-Reviewed Original ResearchMelanoma-specific survivalWorse melanoma-specific survivalHistologic subtypeNodular melanomaNYU cohortSEER cohortMetastatic settingSystemic therapyPrimary histologic subtypeCheckpoint inhibitor immunotherapyMultivariate Cox modelThick primary tumorsDifferent clinical behaviorPrimary nodular melanomaNext-generation sequencingSignificant predictorsClinical Trial ReportingLow mutational burdenMutational landscapeHigh mitotic indexSpecific survivalWorse prognosisClinical behaviorPrimary tumorMelanoma survival